The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Are The Forecasted Market Size Figures For The Curosurf (Poractant Alfa) Market In 2026 And 2030?
The expansion observed during the historical timeframe is attributable to a significant occurrence of premature births, the demonstrated effectiveness in treating respiratory distress syndrome, the extensive implementation of Neonatal Intensive Care Units, medical directives advocating for surfactant treatment, and a subsequent decline in infant death rates.
The growth in the projected timeframe is primarily driven by factors such as a global rise in premature birth rates, the expansion of neonatal intensive care unit (NICU) infrastructure, improved access to neonatal care, heightened awareness regarding early intervention for Respiratory Distress Syndrome (RDS), and ongoing clinical validation.
Key developments expected during the forecast period include the increasing application in neonatal intensive care settings, the growing acceptance of synthetic surfactants, a stronger focus on managing preterm births, the standardization of RDS treatment protocols, and a broader availability of hospital-based neonatal therapies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19893&type=smp
Which Growth Factors Are Strengthening The Curosurf (Poractant Alfa) Market Landscape?
The curosurf (poractant alfa) market is anticipated to experience growth driven by the rising incidence of respiratory disorders. These common conditions, such as asthma, COPD, and lung cancer, impact the lungs and breathing, leading to compromised lung function and breathing difficulties. The increasing occurrence of respiratory disorders is linked to higher air pollution, which exacerbates issues like asthma, and an aging global population, contributing to a greater prevalence of age-related illnesses such as COPD. Poractant alfa is employed in the treatment of neonatal respiratory distress syndrome to enhance lung function and aid breathing in premature infants, administered via an endotracheal tube. For example, the National Library of Medicine, a US-based medical library, reported in December 2023 that the worldwide count of chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older is projected to increase by 23% by 2050, reaching almost 600 million. Thus, the escalating prevalence of respiratory disorders is a significant force behind the expansion of the curosurf (poractant alfa) market.
Curosurf (Poractant Alfa) Market Driver: Growing Prevalence Of Premature Births Driving The Growth Of The Curosurf (Poractant Alfa) Market
How Is The Curosurf (Poractant Alfa) Market Distributed Across Key Segments?
The curosurf (poractant alfa) market covered in this report is segmented –
1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace
3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders
4) By End User: Hospitals, Clinics, Ambulance Services
Which Trends Are Contributing To Changes In The Curosurf (Poractant Alfa) Market?
Leading companies within the curosurf (poractant alfa) market are prioritizing the creation of advanced remedies, such as innovative inhaled gene therapy, to address crucial gaps in managing respiratory conditions. This groundbreaking approach, novel inhaled gene therapy, involves the direct delivery of therapeutic genes into the lungs via inhalation, typically through aerosolized particles or nanoparticles. Illustratively, in November 2024, AlveoGene, a UK-based developer specializing in gene therapy, was granted Rare Pediatric Disease Designation (RPDD) by the FDA for its product AVG-002. AVG-002 represents an innovative inhaled gene therapy aimed at lethal neonatal surfactant protein B (SP-B) deficiency, a severe genetic disorder that leads to respiratory failure in infants. SP-B deficiency, which arises from mutations in the SFTPB gene, currently offers restricted treatment options, primarily dependent on lung transplantation. AVG-002 leverages AlveoGene’s InGenuity platform to introduce a functional SP-B gene directly into the lungs, having demonstrated promising outcomes in preclinical investigations.
Who Are The Businesses Driving Activity In The Curosurf (Poractant Alfa) Market?
Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A
Access The Complete Curosurf (Poractant Alfa) Market Report:
https://www.thebusinessresearchcompany.com/report/curosurf-poractant-alfa-global-market-report-
Which Region Contributes The Most To The Curosurf (Poractant Alfa) Market?
North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model